Loading
A phase 2 trial of Olvimulogene nanivacirepvec, Nivolumab, Cemiplimab in non-small-cell lung cancer and small-cell lung cancer, run by Genelux Corporation, now recruiting.
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer is a phase 2 interventional study registered as NCT06463665 by Genelux Corporation, with 142 participants planned, started 2024-09-26 and due to reach its primary completion in 2027-02. Interventions recorded: Olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin or cisplatin, Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC, Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab, Docetaxel. Conditions listed: Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma. No results are recorded here; the registry entry is the source.
Shares Genelux, Olvimulogene nanivacirepvec.
Shares Cemiplimab, Atezolizumab, Nivolumab, Small-cell lung cancer.
Shares Docetaxel, Nivolumab, Small-cell lung cancer, Cytotoxic chemotherapy.
Shares Atezolizumab, Durvalumab, Nivolumab, Small-cell lung cancer.
Shares Docetaxel, Small-cell lung cancer, Cytotoxic chemotherapy, Non-small-cell lung cancer.
Shares Docetaxel, Small-cell lung cancer, Cytotoxic chemotherapy, Non-small-cell lung cancer.
Shares Atezolizumab, Durvalumab, Nivolumab, Small-cell lung cancer.
Shares Cemiplimab, Atezolizumab, Nivolumab, Cytotoxic chemotherapy.